Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Tamer Othman, Paul Frankel, Pamela Allen, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V. Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T. Rosen, Elad Sharon, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2021-151188

Published: 2021

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD

Blood (2015) 126 (23): 2731.

https://doi.org/10.1182/blood.V126.23.2731.2731

Published: 2015

Journal Articles

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Tanya Siddiqi, MD, Paul Frankel, PhD, Chris Ruel, MS, Robert W Chen, MD, Kevin R. Kelly, MD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, MD PhD, Edward Newman, PhD

Blood (2014) 124 (21): 4483.

https://doi.org/10.1182/blood.V124.21.4483.4483

Published: 2014

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Mark Kirschbaum, MD, Anthony Selwyn Stein, M.D., Paul Frankel, Leslie Popplewell, M.D., Robert w Chen, Maria L Delioukina, MD, Ryotaro Nakamura, MD, David S. Snyder, MD, Cynthia Slape, Christopher Ruel, Joel Conrad, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 528.

https://doi.org/10.1182/blood.V116.21.528.528

Published: 2010

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Mark Kirschbaum, MD, Leslie Popplewell, M.D., Maria L Delioukina, MD, Robert w Chen, Vinod Pullarkat, Paul Frankel, Joel Conrad, Joyce Hartshorn, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 3957.

https://doi.org/10.1182/blood.V116.21.3957.3957

Published: 2010

Journal Articles

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Firoozeh Sahebi, M.D., Amrita Krishnan, M.D., Leonardo Farol, MD, Ji-Lian Cai, MD, George Somlo, MD, Leslie Popplewell, M.D., R. Spielberger, M.D., Neil Martin Kogut, MD, Chatchada Karanes, MD, Christopher Ruel, Paul Frankel, Eunicia Reburiano, Margret O'Donnell, MD, Stephen Forman

Blood (2010) 116 (21): 2399.

https://doi.org/10.1182/blood.V116.21.2399.2399

Published: 2010

Journal Articles

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Mark Kirschbaum, MD, Maria Delioukina, Leslie Popplewell, MD, David S. Snyder, MD, Pablo Parker, Robert Chen, MD, Jasmine Zain, MD, Deron Matsuoka, Nony Obadike, Paul Frankel, Auayporn P. Nademanee, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 1682.

https://doi.org/10.1182/blood.V114.22.1682.1682

Published: 2009

Journal Articles

A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.

Firoozeh Sahebi, Amrita Krishnan, MD, FACP, George Somlo, MD, Leslie Popplewell, P. Parker, Ji-Lian Cai, MD, PhD, Len Farol, MD, Ricardo Spielberger, Neil Martin Kogut, MD, Chatchada Karanes, Christopher Ruel, Paul Frankel, Fermin Arceo, Lupe Duarte, CRRC, Margaret O'Donnell, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 3403.

https://doi.org/10.1182/blood.V114.22.3403.3403

Published: 2009

Journal Articles

Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).

George Somlo, M.D., F.A.C.P., Ricardo Spielberger, MD, Paul Frankel, Chatchada Karanes, MD, Amrita Krishnan, MD, FACP, Pablo Miguel Parker, MD, Leslie Popplewell, Firoozeh Sahebi, Tim Schultheiss, Neil Martin Kogut, MD, An Liu, David S. Snyder, MD, Stephen J. Forman, Jeffrey Y. Wong

Blood (2008) 112 (11): 3326.

https://doi.org/10.1182/blood.V112.11.3326.3326

Published: 2008

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

Mark Kirschbaum, MD, Leslie Popplewell, Auayporn P. Nademanee, Vinod Pullarkat, Maria Delioukina, Jasmine M. Zain, Deron Matsuoka, Bernadette Pulone, Paul Frankel, Igor Espinoza-Delgado, MD, Stephen J. Forman, David Gandara, Edward Newman

Blood (2008) 112 (11): 1564.

https://doi.org/10.1182/blood.V112.11.1564.1564

Published: 2008

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

Mark H. Kirschbaum, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Vinod Pullarkat, MD, Auayporn P. Nademanee, MD, Maria L. Delioukina, MD, Bernadette Pulone, RN, Deron Matsuoka, BS, Paul Frankel, PhD, Zwiebel A. James, MD, Stephen J. Forman, MD, Edward Newman, PhD, David Gandara, MD

Blood (2007) 110 (11): 2568.

https://doi.org/10.1182/blood.V110.11.2568.2568

Published: 2007

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark H. Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, John Wright, MD, Bernadette Pulone, RN, Amalia Rincon, Paul Frankel, PhD, Stephen J. Forman, MD, Edward Newman, PhD

Blood (2007) 110 (11): 891.

https://doi.org/10.1182/blood.V110.11.891.891

Published: 2007

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, John J. Wright, MD, Bernadette Pulone, RN, Amalia Rincon, MA, Paul Frankel, PhD, Stephen J. Forman, MD, Newman Edward, PhD

Blood (2006) 108 (11): 1948.

https://doi.org/10.1182/blood.V108.11.1948.1948

Published: 2006

Journal Articles

Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.

George Somlo, MD, Stephen Forman, MD, Leslie Poppelwell, MD, Tim Schultheiss, PhD, Paul Frankel, Ph.D, Amrita Krishnan, MD, An Liu, PhD, Firoozeh Sahebi, MD, Parker Pablo, MD, Jeffrey Wong, MD

Blood (2005) 106 (11): 1176.

https://doi.org/10.1182/blood.V106.11.1176.1176

Published: 2005

Journal Articles

Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma.

George Somlo, MD, William Bellamy, PhD, Todd M. Zimmerman, MD, Paul Frankel, PhD, Joe Tuscano, MD, Margaret O’Donnell, MD, Ann Mohrbacher, MD, Stephen Forman, MD, Helen Chen, MD, James Doroshow, MD, David Gandara, MD

Blood (2005) 106 (11): 2571.

https://doi.org/10.1182/blood.V106.11.2571.2571

Published: 2005

NARROW

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.

Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.

Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only